Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35042228.
- Also identified by DOI 10.1038/s41591-022-01700-x and PMC identifier 8938268.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) variant of concern (VOC) has destabilized global efforts to control the impact of coronavirus disease 2019 (COVID-19). Recent data have suggested that B.1.1.529 can readily infect people with naturally acquired or vaccine-induced immunity, facilitated in some cases by viral escape from antibodies that neutralize ancestral SARS-CoV-2. However, severe disease appears to be relatively uncommon in such individuals, highlighting a potential role for other components of the adaptive immune system. We report here that SARS-CoV-2 spike-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells induced by prior infection or BNT162b2 vaccination provide extensive immune coverage against B.1.1.529. The median relative frequencies of SARS-CoV-2 spike-specific CD4<sup>+</sup> T cells that cross-recognized B.1.1.529 in previously infected or BNT162b2-vaccinated individuals were 84% and 91%, respectively, and the corresponding median relative frequencies for SARS-CoV-2 spike-specific CD8<sup>+</sup> T cells were 70% and 92%, respectively. Pairwise comparisons across groups further revealed that SARS-CoV-2 spike-reactive CD4<sup>+</sup> and CD8<sup>+</sup> T cells were functionally and phenotypically similar in response to the ancestral strain or B.1.1.529. Collectively, our data indicate that established SARS-CoV-2 spike-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses, especially after BNT162b2 vaccination, remain largely intact against B.1.1.529.
Medical subject headings
- CD4-Positive T-Lymphocytes
- CD8-Positive T-Lymphocytes
- COVID-19
- Cross Protection
- SARS-CoV-2